Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 4/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6981722 | 0.86 | L3MBTL1 (0.44) | L3MBTL1LMNALTA4HEGLN1MMP2 | |
| SCHEMBL6981729 | 0.86 | L3MBTL1 (0.44) | L3MBTL1LMNALTA4HEGLN1MMP2 | |
| SCHEMBL14567550 | 0.82 | MAP4K4 (0.39) | LMNALTA4HMAP4K4MAPTTSHR | |
| SCHEMBL4186244 | 0.78 | CYP1A2 (0.41) | L3MBTL1EGLN1MAPT | |
| SCHEMBL13349554 | 0.71 | L3MBTL1 (0.58) | L3MBTL1LTA4HMMP2MAP4K4TSHR | |
| SCHEMBL8684270 | 0.71 | L3MBTL1 (0.50) | L3MBTL1LTA4HMMP2TSHRFFAR1 | |
| SCHEMBL1807043 | 0.69 | L3MBTL1 (0.72) | L3MBTL1LMNAMMP2MAPTTSHR | |
| SCHEMBL13349555 | 0.68 | L3MBTL1 (0.43) | L3MBTL1LMNALTA4HMMP2TSHR | |
| SCHEMBL9559951 | 0.67 | CYP1A2 (0.62) | L3MBTL1LMNAMAPTTSHRFFAR1 | |
| SCHEMBL14573199 | 0.67 | MAP4K4 (0.39) | L3MBTL1LTA4HMAP4K4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183379-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090069372-A1 | ANTITUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-12 | — | — | US | disclosed |
| US-7470788-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2008-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069372-A1 | ANTITUMOR AGENTS | NHERF1, BACH1, MCL1 | L3MBTL1 3840/4885LMNA 3294/4885LTA4H 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.